Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States

详细信息    查看全文

• 作者：J. Quentin Clemens^a ; ^{qclemens@umich.edu" class="auth_mail" title="E-mail the corresponding author} ; Howard B. Goldman^b ; Kelly H. Zou^c ; ^&dagger ; ; Xuemei Luo^c ; ^&dagger ; ; David Russell^c ; ^&dagger ; ; Douglass S. Chapman^c ; ^&dagger ; ; Canan B. Esinduy^c ; ^&dagger ; ; Jennifer T. Anger^d ; ^&Dagger ;
• 关键词：prostatic hyperplasia ; diagnostic tests ; routine ; 5-alpha reductase inhibitors ; standards ; prostate-specific antigen
• 刊名：The Journal of Urology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：196
• 期：1
• 页码：173-178
• 全文大小：122 K

文摘

We examined diagnostic tests and treatment patterns in men with new onset benign prostatic hyperplasia using consolidated national electronic health record data.

Materials and Methods

5">The Humedica® electronic health record database consists of de-identified patient records from approximately 25 million patients in the United States. Using this database, men with a new benign prostatic hyperplasia diagnosis (benign prostatic hyperplasia, bladder neck obstruction, urinary retention and incomplete bladder emptying) between July 1, 2009 and June 30, 2012 were included in study. Exclusion criteria included conditions such as genitourinary cancers, radiation cystitis, neurogenic bladder and urological pain diagnoses. Diagnostic tests and treatments were summarized and stratified by age (less than 65 vs 65 years or greater) and serum prostate specific antigen level.

Results

A total of 38,252 men met inclusion criteria. Mean followup was 1,020 days. Serum creatinine in 92% of patients, serum prostate specific antigen in 76% and urinalysis in 52% were the most common tests. Invasive testing was obtained in less than 20% of patients. Treatments included watchful waiting in 40% of patients, pharmacological therapy in 59.4% and surgery in 2.2%. α-Blockers were prescribed in 50.7% of men. Men older than 65 years and with higher prostate specific antigen levels were less likely to be treated with watchful waiting. Therapy with a 5-ARI (5-α reductase inhibitor) was prescribed in 23% to 29% of men across all prostate specific antigen categories.

Conclusions

5">The majority of clinical care for new onset benign prostatic hyperplasia was in concordance with guideline recommendations. Based on prostate specific antigen values, 5-ARI therapy was underutilized in men with large prostates and was over utilized in men with small prostates.